Stroke Rehabilitation Outcome During COVID-19 Lockdown
Launched by JEREMIA HELD · Apr 30, 2020
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
With 16'000 patients hospitalized and with new permanent disability in approximately 7'000 individuals every year in Switzerland, stroke has a major impact on quality of life and is an enormous socioeconomic burden. Virtually all patients receive inpatient rehabilitation in the sub-acute phase poststroke. However, also in the later phases poststroke, patients receive rehabilitation interventions in outpatient rehabilitation clinics and private practices, with goal to improve or maintain their functional capacity.
Currently, Switzerland finds itself in an extraordinary situation. The Federa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ischemic or haemorrhagic stroke, confirmed by MRI-DWI and/or CT
- • Participating in a stroke research project before the Lockdown (ESTREL - BASEC Nr. 2018-02021/ RE-USE - BASEC-Nr. 2017-01070)
- • Age 18 years or older
- • Verbal and written informed consent of the patient after participants' information
- Exclusion Criteria:
- • Severe communication or cognitive deficits, that cause inability to follow the procedures
About Jeremia Held
Jeremia Held is a dedicated clinical trial sponsor focused on advancing innovative therapeutic solutions through rigorous research and development. Committed to improving patient outcomes, the organization collaborates with leading healthcare professionals and institutions to design and conduct high-quality clinical studies. With a strong emphasis on ethical practices and regulatory compliance, Jeremia Held strives to ensure the safety and efficacy of new treatments while fostering transparency and integrity throughout the clinical trial process. Their mission is to contribute to the scientific community and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Andreas R Luft, Prof
Study Chair
University of Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials